How Experimental Treatments Are Treated in Clinical Negligence

Experimental treatments - sometimes described as novel, unproven, innovative or non‑standard therapies - raise particular legal and ethical questions when they are offered to patients. In the context of clinical negligence claims in England and Wales, experimental treatments intersect with key legal principles such as informed consent, duty of care, causation and compensation. This article explains how experimental treatments are treated legally when claims arise, outlines patients' rights and the responsibilities of healthcare professionals, and provides practical guidance for patients and their advisers. Content is based on authoritative legal sources, case law and established legal principles.

What Counts as an Experimental Treatment?

There is no single statutory definition of “experimental treatment” in UK law. However, it is commonly understood to include:

• Medical procedures or therapies that have not yet been fully validated through established clinical practice.
• Use of innovative techniques or emerging technologies.
• Treatments offered before regulatory licensing or widespread adoption, outside formal clinical trials.

Patients may pursue experimental options when conventional treatments have failed, are unavailable or carry significant limitations. Experimental treatments can include unlicensed medicines, gene or stem cell therapies, novel surgical procedures and other advanced therapies.

Legal Framework for Clinical Negligence

Clinical negligence law in England and Wales requires that a claimant demonstrates:

1. A duty of care was owed by the healthcare professional to the patient.
2. There was a breach of that duty - the standard of care fell below that reasonably expected of a competent clinician.
3. The breach caused the patient to suffer harm or loss.

For experimental treatments, the focus is not on whether the treatment itself was “experimental” but on whether the information provided to the patient and the decision‑making process met legal standards.

Informed Consent: The Core Legal Principle

Experimental treatments are principally governed by the law of informed consent. Before any non‑emergency treatment, healthcare professionals must secure valid consent by ensuring the patient understands:

• The nature and purpose of the treatment.
• Material risks and potential benefits.
• Alternative treatments, including the option of no treatment.

The leading authority in English medical law on informed consent is Montgomery v Lanarkshire Health Board [2015] UKSC 11, in which the Supreme Court established that clinicians must take reasonable care to ensure patients are aware of material risks and reasonable alternatives. What is material is judged from the perspective of a reasonable person in the patient's position, and what that particular patient would likely find significant.

Implications of Montgomery for Experimental Treatments

Montgomery's principles apply with particular force where treatments are experimental:

• Patients must be informed that a proposed treatment is experimental or non‑standard.
• Material risks associated with uncertainty, lack of long‑term evidence or unestablished outcomes must be disclosed.
• Alternative options - including established therapies, clinical trials or palliative care - must be discussed where reasonable and relevant.

Consent is a process, not merely the signature on a form. This is especially true for experimental treatments where the uncertainty of outcomes and the balance of risks and benefits can be complex.

Differences Between Standard and Experimental Treatment Claims

Standard Treatments

In cases involving established medical practice, courts assess negligence by examining whether the clinician met the expected standard of care, historically informed by the Bolam test (a professional practice standard). Although Bolam still applies to clinical judgement about treatment, Montgomery replaced Bolam for informed consent questions.

Experimental Treatments

With experimental treatments, informed consent takes centre stage. Because evidence, outcomes and professional consensus may be less well‑defined, accurate and comprehensive communication becomes critical. If a clinician fails to disclose risks associated with the experimental nature of a treatment or reasonable alternatives, this can form the basis of a clinical negligence claim even if the treatment was administered competently.

Regulatory and Ethical Considerations

Experimental treatments may be offered through:

• Clinical trials under specific research governance frameworks.
• Compassionate use schemes or early access programmes for unlicensed treatments.
• Specialist centres offering innovative procedures under professional practice policies.

Even when treatment is lawful and ethically justified, clinicians must still ensure valid consent. The ethical duty to respect patient autonomy overlaps substantially with legal requirements in clinical negligence.

Causation and Experimental Treatments

In a clinical negligence claim, it is not enough to show that consent was inadequately obtained; claimants must also prove causation - that harm was caused by the breach of duty (e.g., failure to disclose material risks). A failure to explain the experimental nature of a treatment might result in a claim where the claimant would have chosen an alternative had they been properly informed.

Practical Examples

Case of Inadequate Consent to Experimental Surgery

Suppose a patient undergoes an innovative surgical procedure that carries uncertain long‑term risks. If the surgeon fails to explain that the treatment is experimental, the possibility of unknown outcomes, and viable alternatives, a court may find that the patient did not give valid informed consent. If the patient suffers harm that they would have sought to avoid with full information, this may give rise to a clinical negligence claim under informed consent principles.

Participation in a Trial vs. Standard Treatment

When a patient participates in a clinical trial, the consent process is usually governed by research law and regulatory standards. In contrast, an experimental treatment offered outside a formal trial still triggers common law duties of disclosure and consent. The key question remains whether the patient understood the experimental status and risks involved.

Time Limits and Legal Process

Clinical negligence claims in England and Wales are generally subject to a three‑year limitation period from the date of injury or knowledge of harm. Informed consent claims involving experimental treatments are no different. Claimants should seek legal advice promptly to preserve their rights.

Common Questions

Can experimental treatments be refused by a patient?
Yes. Patients have the legal right to refuse treatment, including experimental options, so long as they have capacity to decide.

Does a signed consent form protect clinicians?
No. A signed form is not conclusive. Valid consent requires a meaningful dialogue about risks, benefits and alternatives, tailored to the patient's circumstances.

Can a claim succeed if the experimental treatment was carried out competently?
Yes. A claim can succeed on the basis of lack of informed consent even if the treatment itself was technically competent, if the patient was not adequately informed about material risks and alternatives beforehand.

Final Thoughts

Experimental treatments present legal complexities in clinical negligence claims in England and Wales. The central legal issue is informed consent: a clinician must take reasonable care to ensure the patient understands the experimental nature of the treatment, its risks, benefits and alternatives. Failure to do so can give rise to liability, even where the treatment was executed competently. Claimants should act promptly, gather detailed medical records and seek specialist advice to assess whether the consent process was lawful and whether harm resulted from inadequate disclosure. A clear understanding of patient rights, legal standards and relevant evidence is essential for navigating claims arising from experimental treatments.

James William Steven Parker

James is the founder of UKLegalGuides.com and a former agent at the Ministry of Justice (UK). With a background in processing legal claims, he launched this platform to make the laws of England and Wales accessible to everyone.